Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: A joint modelling approach

MASTERMIND consortium, John M. Dennis, Beverley M. Shields, Angus G. Jones, Ewan Pearson, Andrew T. Hattersley, William E. Henley (Lead / Corresponding author)

Research output: Contribution to journalArticle

5 Citations (Scopus)
83 Downloads (Pure)

Abstract

Objective: Precision medicine drug therapy seeks to maximise efficacy and minimise harm for individual patients. This will be difficult if drug response and side-effects are positively associated, meaning patients likely to respond best are at increased risk of side-effects. We applied joint longitudinal-survival models to evaluate associations between drug response (longitudinal outcome) and risk of side-effects (survival outcome) for patients initiating type 2 diabetes therapy.

Study Design and Setting: Participants were randomised to metformin, sulfonylurea or thiazolidinedione therapy in the ADOPT drug-efficacy trial (n=4,351). Joint models were parameterised for: 1) current HbA1c response (change from baseline in HbA1c); 2) cumulative HbA1c response (total HbA1c change).

Results: With metformin, greater HbA1c response did not increase risk of gastrointestinal events (Hazard ratio (HR) per 1% absolute greater current response 0.82 (95% confidence interval 0.67,1.01); HR per 1% higher cumulative response 0.90 (0.81,1.00)). With sulfonylureas, greater current response was associated with increased risk of hypoglycaemia (HR 1.41 (1.04,1.91)). With thiazolidinediones, greater response was associated with increased risk of oedema (current HR 1.45 (1.05,2.01); cumulative 1.22 (1.07,1.38)) but not fracture.

Conclusion: Joint modelling provides a useful framework to evaluate the association between response to a drug and risk of developing side-effects. There may be great potential for widespread application of joint modelling to evaluate the risks and benefits of both new and established medications.
Original languageEnglish
Pages (from-to)1869-1877
Number of pages9
JournalClinical Epidemiology
Volume10
DOIs
Publication statusPublished - 14 Dec 2018

Keywords

  • diabetes mellitus, type 2
  • Drug-Related Side Effects and Adverse Reactions
  • Glycated-Hemoglobin A
  • Hypoglycemia
  • Joint model
  • Precision Medicine

Fingerprint Dive into the research topics of 'Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: A joint modelling approach'. Together they form a unique fingerprint.

  • Profiles

    No photo of Ewan Pearson

    Pearson, Ewan

    Person: Academic

    Cite this

    MASTERMIND consortium, Dennis, J. M., Shields, B. M., Jones, A. G., Pearson, E., Hattersley, A. T., & Henley, W. E. (2018). Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: A joint modelling approach. Clinical Epidemiology, 10, 1869-1877. https://doi.org/10.2147/CLEP.S179555